The ECCO guidelines list various factors that could determine the way forward in the maintenance of UC, such as disease extent and the intensity and frequency of flares.
Lilly Gastroenterology
Pharmaceutical Manufacturing
Channel for the Professional Gastroenterology Community. Follow us for useful Gastroenterology info.
About us
Lilly unites caring with discovery to make life better for people around the world. When you engage with Lilly on LinkedIn (and any other of Lilly’s social media channels), you are agreeing to these Community Guidelines in addition to the Terms and Conditions or other legal notices provided by Lilly and those of LinkedIn.
- Website
-
https://e.lilly/4bSHvqm
External link for Lilly Gastroenterology
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
Updates
-
Although no biomarker is an alternative to endoscopy in ulcerative colitis, studies are emerging showing correlations between biomarkers and different stages of disease, suggesting they could be used to avoid frequent endoscopy. Non-invasive biomarkers such as faecal calprotectin, faecal lactoferrin, and serum C-reactive protein can be used to monitor UC. Faecal biomarkers are particularly useful in patients where they historically correlate with endoscopic disease activity. However, there can be variations in biomarker elevation among individuals with intestinal inflammation, and in some cases, they may not align well with endoscopic activity. The confidence of these biomarkers may be higher when they have been longitudinally observed to correlate with endoscopic disease activity in an individual patient.¹⁻³ What do you think?
-